Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants

Sleep Medicine

Volumn 4, Issue 1, 2003, Pages 43-49

  Schwartz, Jonathan R L ^a   Feldman, Neil T ^b   Fry, June M ^c   Harsh, John ^d  

^a INTEGRIS BAPTIST MEDICAL CENTER   (United States)

^b St Petersburg Sleep Disord Center   (United States)

^c Center for Sleep Medicine   (United States)

^d UNIVERSITY OF SOUTHERN MISSISSIPPI   (United States)

Author keywords

Dextroamphetamine; Excessive daytime sleepiness; Methylphenidate; Modafinil; Pemoline; Wakefulness

Indexed keywords

DEXAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; PEMOLINE; PSYCHOSTIMULANT AGENT;

ADULT; AGED; AGITATION; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; MALE; MOOD DISORDER; MULTICENTER STUDY; NARCOLEPSY; NAUSEA; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; TACHYCARDIA; WAKEFULNESS;

EID: 0037214622     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1389-9457(02)00240-x     Document Type: Article

References (31)

1. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996. pp. 199-248.
2. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994;17:352-371.
3. Miller NS, Millman RB, Gold MS. Amphetamines: pharmacology, abuse and addiction. Adv Alcohol Subst Abuse 1989;8:53-69.
4. Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000;23:149-156.
5. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 1996;93:14128-14133.
6. Engber TM, Dennis SA, Jones BE, Miller MS, et al. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Neuroscience 1998;87:905-911.
7. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8628.
8. Boivin DB, Montplaisir J, Petit D, Lambert C, et al. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993;16:46-53.
9. Besset A, Chetrit M, Carlander B, Billiard M. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiol Clin 1996;26:60-66.
10. Broughton RJ, Fleming JA, George CF, Hill JD, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-451.
11. Billiard M, Besset A, Montplaisir J, Laffont F, et al. Modafinil: a double-blind multicentric study. Sleep 1994;17:S107-S112.
12. U.S. Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97.
13. U.S. Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175.
14. Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000;1:109-116.
15. Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C. Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 2000;1:231-243.
16. Cassel W, Heitmann J, Kemeny C, Peter JH. Effects of modafinil on vigilance and daytime sleepiness in sleepy patients with mild to moderate sleep disordered breathing. Sleep 1998;21:92.
17. Arnulf I, Homeyer P, Garma L, Whitelaw WA, et al. Modafinil in obstructive sleep apnea-hypopnea syndrome: a pilot study in 6 patients. Respiration 1997;64:159-161.
18. Pack AI, Black JE, Schwartz JRL, Matheson JK, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001;164:1675-1681.
19. Kingshott RN, Vennelle M, Coleman EL, Engleman HM, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001;163:918-923.
20. Beusterien KM, Rogers AE, Walsleben JA, Emsellem HA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22:757-765.
21. Hirshkowitz M, Schwartz JRL, Corser B, Sahota P. Long-term (136 weeks) safety and efficacy of modafinil for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep 2001;24:A329-A330.
22. Emsellem HA. Efficacy and safety profiles of modafinil maintained during long-term (40 and 88 weeks) treatment of excessive daytime sleepiness associated with narcolepsy. Neurology 2000;54:A29-A30.
23. Littner M, Johnson SF, McCall WV, Anderson WM, et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001;24:451-466.
24. Comer AM, Spencer CM. Management of narcolepsy: defining the role of modafinil. Drugs Dis Manag 2000;8:99-111.
25. Guilleminault C, Aftab FA, Karadeniz D, Philip P, et al. Problems associated with switch to modafinil - a novel alerting agent in narcolepsy. Eur J Neurol 2000;7:381-384.
26. Walsleben JA, Ristanovic R, Hirshkowitz M. PROVIGIL® (modafinil) in the treatment of excessive daytime sleepiness in narcolepsy: effect of previous treatment with stimulants on clinical response and safety. Sleep 2000;23:A303-A304.
27. Thorpy MJ. The International Classification of Sleep Disorders: Diagnostic and Coding Manual. Rochester, MN: American Sleep Disorders Association, 1990.
28. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.
29. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: National Institute of Mental Health, US Dept. of Health, Education, and Welfare, 1976.
30. Girish MR, Shepard JW, Silber MH. Change from conventional stimulants to modafinil in patients with narcolepsy or idiopathic hypersomnia. Sleep 2000;23:A302.
31. Pigeau R, Naitoh P, Buguet A, McCann C, et al. Modafinil, d-amphetamine and placebo during 64 h of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995;4:212-228.